Anti-DR5 mAb-treated Tg46 mice showed lower number of tumors per animal (Fig. 7F), delayed appearance of papillomas (Fig. 7G) and lower number of total tumors (Fig. 7H), compared to those treated with control mAb. This evidence concerns the gene TNFRSF10B and papilloma.